

BIOCON GROUP

FACT SHEET

December - 2019

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
	(Rs Cr)	
	December 31, 2019	March 31, 2019
ASSETS		
Non-current assets		
(a) Property, plant and equipment	4,422	4,253
(b) Capital work-in-progress	2,029	1,287
(c) Right-of-use assets	130	-
(d) Goodwill	26	26
(e) Other intangible assets	428	192
(f) Intangible assets under development	565	612
(g) Investments in associates and a joint venture	23	43
(h) Financial assets		
Investments	391	139
Derivative assets	64	71
Other financial assets	39	39
(i) Income-tax asset, net	201	169
(j) Deferred tax asset, net	315	325
(k) Other non-current assets	268	213
	8,900	7,370
Current assets		
(a) Inventories	1,419	1,032
(b) Financial assets		
Investments	511	829
Trade receivables	1,240	1,292
Cash and cash equivalents	515	730
Other bank balances	101	327
Derivative assets	67	78
Other financial assets	642	387
(c) Other current assets	195	149
	4,691	4,823
TOTAL	13,590	12,192
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	300
(b) Other equity	6,012	5,798
Equity attributable to owners of the Company	6,612	6,098
Non-controlling interests	672	609
	7,284	6,707
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,600	1,526
Lease liabilities	78	15
Derivative liability	71	35
(b) Provisions	87	66
(c) Other non-current liabilities	912	805
	2,748	2,447
Current liabilities		
(a) Financial liabilities		
Borrowings	626	261
Lease liabilities	11	1
Trade payables	1,341	1,198
Derivative liability	12	14
Other financial liabilities	1,039	991
(b) Provisions	105	81
(c) Income tax liability, net	217	124
(d) Other current liabilities	207	369
	3,558	3,039
TOTAL	13,590	12,192

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	9M FY 2020	9M FY 2019	Variance
INCOME			
Small molecules	1,553	1,301	19%
Biologics	1,594	1,066	50%
Branded formulations	419	523	-20%
Research services	1,405	1,292	9%
Inter-segment	(184)	(196)	-6%
Revenue from operations #	4,786	3,986	20%
Other income	98	121	-19%
TOTAL REVENUE	4,885	4,107	19%
EXPENDITURE			
Material & Power costs	1,676	1,588	6%
Staff costs	974	769	27%
Research & Development expenses*	314	198	59%
Other expenses	538	445	21%
Manufacturing, staff & other expenses	3,502	3,000	17%
EBITDA	1,383	1,107	25%
Interest & Finance charges	48	55	-12%
Depreciation & Amortisation	400	328	22%
Share of profit in JV / Associate, net	21	(12)	-269%
PBT BEFORE EXCEPTIONAL ITEM	914	736	24%
Exceptional item, Net	68	195	-
PBT	982	931	6%
Taxes	205	153	34%
Taxes on exceptional item	66	18	-
NET PROFIT BEFORE MINORITY INTEREST	712	760	-6%
Minority interest	73	68	8%
Minority interest on exceptional item	14	-	-
NET PROFIT FOR THE PERIOD	625	692	-10%
EPS Rs.	5.2	5.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	637	516	23%
Exceptional item, net of taxes	(12)	176	
NET PROFIT FOR THE PERIOD	625	692	-10%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	23	18	
* Gross Research & Development expenses	388	314	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 20	Q3 FY 19	Variance
INCOME			
Small molecules	544	469	16%
Biologics	588	449	31%
Branded formulations	157	212	-26%
Research services	519	467	11%
Inter-segment	(60)	(56)	8%
Revenue from operations #	1,748	1,541	13%
Other income	36	25	40%
TOTAL REVENUE	1,784	1,566	14%
EXPENDITURE			
Material & Power costs	636	590	8%
Staff costs	342	269	27%
Research & Development expenses*	131	77	71%
Other expenses	194	224	-13%
Manufacturing, staff & other expenses	1,304	1,160	12%
EBITDA	480	406	18%
Interest & Finance charges	18	19	-5%
Depreciation & Amortisation	144	117	23%
Share of profit in JV / Associate, net	3	(13)	-126%
PBT BEFORE EXCEPTIONAL ITEM	315	283	11%
Exceptional item, Net	-	6	-100%
PBT	315	289	9%
Taxes	63	46	37%
Taxes on exceptional item	22	-	-
NET PROFIT BEFORE MINORITY INTEREST	230	243	-5%
Minority interest	28	26	6%
NET PROFIT FOR THE PERIOD	203	217	-7%
EPS Rs.	1.7	1.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	225	211	6%
Exceptional item, net of taxes	(22)	6	
NET PROFIT FOR THE PERIOD	203	217	-7%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	9	7	
* Gross Research & Development expenses	155	106	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 20	Q2 FY 20	Variance
INCOME			
Small molecules	544	530	3%
Biologics	588	516	14%
Branded formulations	157	128	23%
Research services	519	465	12%
Inter-segment	(60)	(66)	-9%
Revenue from operations #	1,748	1,572	11%
Other income	36	38	-7%
TOTAL REVENUE	1,784	1,611	11%
EXPENDITURE			
Material & Power costs	636	549	16%
Staff costs	342	322	6%
Research & Development expenses*	131	104	26%
Other expenses	194	194	0%
Manufacturing, staff & other expenses	1,304	1,169	12%
EBITDA	480	441	9%
Interest & Finance charges	18	14	27%
Depreciation & Amortisation	144	132	9%
Share of profit in JV / Associate, net	3	9	-66%
PBT BEFORE EXCEPTIONAL ITEM	315	286	10%
Exceptional item, Net	-	68	-
PBT	315	354	-11%
Taxes	63	73	-14%
Taxes on exceptional item	22	27	-18%
NET PROFIT BEFORE MINORITY INTEREST	230	254	-9%
Minority interest	28	24	13%
Minority interest on exceptional item	-	14	
NET PROFIT FOR THE PERIOD	203	216	-6%
EPS Rs.	1.7	1.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	225	189	19%
Exceptional item, net of taxes	(22)	27	
NET PROFIT FOR THE PERIOD	203	216	-6%
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	9	7	
* Gross Research & Development expenses	155	123	